Report
Jacob Mekhael

MaaT Pharma Completes EU regulatory submission for MaaT013 in aGvHD

MaaT announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013 (microbiome therapy, enema formulation) in aGvHD under the brand name Xervyteg. Potential approval could be granted in 2H26, and MaaT is actively exploring strategic partnerships to commercialise MaaT013 in Europe. We believe the solid phase 3 results and good uptake in the early access program will be supportive of MaaT013's commercial launch if approved. We reiterate our € 17 TP and Buy rating.
Underlying
MAAT PHARMA SA

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Jacob Mekhael

Other Reports on these Companies
Other Reports from KBC Securities
Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch